EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Rhea-AI Summary

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has announced its participation in several upcoming conferences aimed at improving the lives of patients with serious eye disorders. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 a.m. ET, and at the Baird 2022 Global Healthcare Conference on September 14, 2022, at 1:25 p.m. ET. Additionally, a Fireside Chat at the Guggenheim Nantucket Therapeutics Conference is scheduled for September 29, 2022, at 10:30 a.m. ET, followed by another on September 30, 2022, at 11:40 a.m. ET during the Benzinga Retail Conference.

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

• H.C. Wainwright 24^th Annual Global Investment Conference
  Forum: Corporate Presentation
  Date: Monday, September 12, 2022
  Time: 7:00 a.m. ET

• Baird 2022 Global Healthcare Conference
  Forum: Corporate Presentation
  Date: Wednesday, September 14, 2022
  Time: 1:25 p.m. ET

• Guggenheim Nantucket Therapeutics Conference
  Forum: Fireside Chat
  Date: Thursday, September 29, 2022
  Time: 10:30 a.m. ET

• Benzinga Retail Conference (Virtual)
  Forum: Fireside Chat
  Date: Friday, September 30, 2022
  Time: 11:40 a.m. ET

A webcast and subsequent archived replay of the corporate presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:

Christina Tartaglia
Stern IR
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

What conferences will EyePoint Pharmaceuticals present at in September 2022?

EyePoint Pharmaceuticals will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, the Baird 2022 Global Healthcare Conference on September 14, the Guggenheim Nantucket Therapeutics Conference on September 29, and the Benzinga Retail Conference on September 30.

What is the date and time of EyePoint Pharmaceuticals' presentation at the H.C. Wainwright Conference?

The presentation at the H.C. Wainwright 24th Annual Global Investment Conference is scheduled for September 12, 2022, at 7:00 a.m. ET.

When will EyePoint Pharmaceuticals participate in the Benzinga Retail Conference?

EyePoint Pharmaceuticals will participate in the Benzinga Retail Conference on September 30, 2022, at 11:40 a.m. ET.

How can I access EyePoint Pharmaceuticals' conference presentations?

You can access the webcast and archived replay of EyePoint Pharmaceuticals' conference presentations via the Investors section of their website.

What is the main focus of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals focuses on developing and commercializing therapeutics to improve the lives of patients with serious eye disorders.